How to Audit Your Audit Risks and Legal Exposure Management Process Before Inspectors Do

Context

In the highly regulated pharmaceutical and biotech industries, audit risks and legal exposure management are paramount, especially concerning controlled substances compliance. These regulations are designed to maintain patient safety and ensure efficacy while minimizing the potential for misuse. Regulatory Affairs (RA) professionals carry the significant responsibility of ensuring that their organizations adhere to the guidelines set forth by various health authorities, including the FDA, EMA, and MHRA. This article provides a structured approach to auditing your processes to identify and mitigate risks associated with controlled substances compliance.

Legal/Regulatory Basis

The regulatory framework surrounding controlled substances varies between regions, but certain core principles remain consistent. In the United States, Title 21 of the Code of Federal Regulations (CFR) Part 1300 to Part 1399 outlines the legal classification of controlled substances. In the EU, the directives and regulations from the European Medicines Agency (EMA) play a similar role, requiring rigorous compliance for marketing authorization holders and qualified persons in medicine. The UK follows suit with stringent guidelines, especially post-Brexit under the supervision of the Medicines and Healthcare products Regulatory Agency (MHRA).

Key Regulations to Note

• 21 CFR Part 1300 – Lists controlled substances and their classifications.
• EMA Guidelines – Includes directives on handling controlled substances in clinical trials and marketing authorizations.
• MHRA Regulations – Necessary guidelines for market license in the UK.

Documentation Requirements

For effective audit risks and legal exposure management, comprehensive documentation is essential. Companies must maintain clear records that demonstrate compliance with regulations governing controlled substances. Key documentation includes:

• Standard Operating Procedures (SOPs): Clearly define processes related to the handling, storage, and documentation of controlled substances.
• Audit Trails: Maintain detailed logs of all actions taken regarding controlled substances, including inventories and discrepancies.
• Training Records: Document the training provided to staff regarding the legal compliance and handling of controlled substances.
• Incident Reports: Record any compliance failures or incidents, along with corrective actions taken.

Review/Approval Flow

The review and approval process within regulatory submissions must align with the guidelines. Below is a structured flow for audits related to controlled substances:

1. Pre-Submission Audit: Evaluate all documentation against regulatory requirements.
2. Submission Preparation: Ensure that all documents are compiled accurately, reflective of current practices.
3. Regulatory Review: Submit the documentation to regulatory authorities, while preparing responses for potential queries.
4. Post-Submission Auditing: Maintain oversight on any submission decisions, identifying lessons learned for future submissions.

Common Deficiencies and How to Avoid Them

During inspections, regulatory agencies often identify deficiencies related to controlled substances compliance. Some of the common deficiencies include:

• Inadequate Record Keeping: Ensure that all records are complete, accurate, and successfully traceable throughout the audit process.
• Lack of Training: Regular training sessions should be held to ensure compliance and update staff on any changes in regulatory requirements.
• Poor Risk Management Practices: Establish robust risk assessment practices, ensuring they are regularly reviewed and updated.
• Non-compliance with SOPs: Routine checks should be in place to ascertain adherence to institutional SOPs.

RA-Specific Decision Points

As regulatory professionals, recognizing when to classify changes in your product or process as a variation versus a new application is crucial for maintaining compliance and timely market access. Here are some decision points:

Variation vs. New Application

Determining whether to file a change request as a variation or a new application hinges on multiple factors:

• Extent of Change: If the change significantly alters the product’s quality, safety, or efficacy, a new application may be warranted.
• Regulatory Guidelines: Consult the specific guidelines of the regulatory body regarding submissions for variations (e.g., variations to the marketing authorization).
• Data Requirements: Assess whether existing data suffices for the variation or if bridging data are necessary for justifying the change.

Bridging Data Justifications

When bridging data is necessary, clear justification must be documented and submitted. Points to consider include:

• Scientific Rationale: Articulate why existing data can extend to the new context without compromising patient safety.
• Comparative Analysis: Provide a thorough comparison of the original and modified parameters to support your rationale.
• Historical Data: Utilize historical data from previously approved submissions to strengthen the justification.

Practical Tips for Documentation and Responses to Agency Queries

When faced with agency queries, prompt and comprehensive responses can greatly alleviate potential compliance issues. Here are some practical tips:

• Timeliness: Respond rapidly to queries to demonstrate adherence to submission timelines and regulatory responsibilities.
• Clarity and Conciseness: Ensure that all documentation and responses are clear, concise, and directly address the agency’s questions.
• Collaborative Review: Conduct internal reviews of responses with cross-functional teams to ensure that all angles are covered, particularly with input from Quality Assurance (QA) and Clinical divisions.
• Documentation Update: Use agency feedback as a basis for updating internal documentation and SOPs to close any identified gaps.

Conclusion

Conducting a thorough review of your audits risks and legal exposure management processes concerning controlled substances compliance can significantly mitigate potential compliance risks. By adhering to the regulatory framework established by authorities like the FDA, EMA, and MHRA, RA professionals can bolster their organizations’ operational integrity and ensure the consistent quality of products offered to patients globally. These steps not only prepare organizations for inspections but also foster a culture of compliance and excellence.